Sign up for free to view insider transactions by individual.
Oppenheimer Maintains Outperform on Zura Bio, Lowers Price Target to $5
Zura Bio discontinues tibulizumab in HS after Phase II trial failure
Guggenheim Maintains Buy on Zura Bio, Lowers Price Target to $8
Zura Bio Discontinues Hidradenitis Suppurativa Development After Phase 2 Tibulizumab Trial Misses Endpoints
Wedbush Maintains Outperform on Zura Bio, Lowers Price Target to $10
Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa
Zura Bio Says Phase 2 TibuSHIELD Study Of Tibulizumab In Hidradenitis Suppurativa Missed Primary And Key Secondary Endpoints
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Files Prospectus To Offer Up To $700M Of Securities
Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio Q3 EPS $(0.20), Inline
This biotech stock is a top pick at Guggenheim
Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply
Zura Bio to Participate in the Cantor Global Healthcare Conference
Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22
Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio Q2 EPS $(0.21) Misses $(0.20) Estimate
William Blair Starts Zura Bio (ZURA) at Outperform
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.